Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-03-03

Clinical Trial Update: FactOr XIa inhibiTion for the pRevention of venOus Thromboembolism in Patients Undergoing Total Knee Arthroplasty [Phase 2]

View source ↗

Summary

Phase 2 trial update of FactOr XIa inhibition for prevention of venous thromboembolism in patients undergoing total knee arthroplasty.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • FactOr XIa inhibition

Snippet

Sponsor: Bayer | Conditions: Knee Arthroplasty, Total | Phase 2 | Status: COMPLETED